Alan H. Bryce, M.D.

Alan H. Bryce, M.D., joined City of Hope® Cancer Center Phoenix as the chief clinical officer in 2023. As a medical oncologist and researcher, Dr. Bryce holds a dual title as professor of department of molecular medicine at Translational Genomics Research Institute (TGen), also part of City of Hope and located in Phoenix. As an oncologist with City of Hope Cancer Center Phoenix, Dr. Bryce focuses his practice on genitourinary cancers, primarily prostate and testicular cancers, with specialized expertise in cancer research and genomics in prostate cancer.  By analyzing a patient's tumor at a molecular level, there is an opportunity to identify individually matched treatments that are not otherwise obvious in a given patient.

In collaboration with his colleagues at TGen, Dr. Bryce is at the forefront of cancer genomics and novel therapeutics for prostate cancer.  His research focuses on cancer genetics, novel therapies and immunotherapeutic approaches in the search for a cure for prostate cancer. Dr. Bryce studies the power of leveraging cancer genomics and believes we can treat each patient with the best drug for his individual situation.

After attending medical school at Finch University of Health Sciences/Chicago Medical School, Dr. Bryce completed a residency in internal medicine at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine. He then finished medical training as chief resident in his hematology and medical oncology fellowship at Mayo Graduate School of Medicine, Mayo Clinic College of Medicine.

Throughout his career, Dr. Bryce has been widely published and received numerous honors and awards.  He is board certified in internal medicine, hematology and medical oncology and is a member of several professional organizations, including the American Association of Clinical Oncology (ASCO), and is the genitourinary chair for Academic and Community Cancer Research United.

AWARDS

• 2021, Research Innovation Award, Department of Medicine, Mayo Clinic
• 2009, Outstanding Trainee Award, Hematology/Oncology Fellowship Program, Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
• 2009, Oncology Scholar-in Training Award, American Association of Cancer Research-Bristol-Myers Squibb
• 2008, Young Investigator Award, American Journal of Hematology
• 2003-2004, Excellence in Teaching Recognition Award, Mayo Medical School, Mayo Clinic College of Medicine
• 1998, Graduation with College Honors, University of California, Los Angeles, Los Angeles, California
• 1993, Eagle Scout, Boy Scouts of America

MEMBERSHIPS

• 2021-present, Academic and Community Cancer Research United, Genitourinary Cancer Chair
• 2003-present, American Society of Clinical Oncology
• 2001-present, Arizona Medical Association
• 2018-2019, National Comprehensive Cancer Network, Policy Advisory Group
• 2016-2017, Society for Melanoma Research
• 2011-2015, The Arizona Clinical Oncology Society (TACOS), Board Member

• First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. JAMA Oncol. 2023 May 1;9(5):635-645. doi: 10.1001/jamaoncol.2022.7762. PMID: 36862387
• Rucaparib or Physician's Choice in Metastatic Prostate Cancer. Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. PMID: 36795891 Free PMC article. Clinical Trial.
• Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials: A Meta-analysis. Riaz IB, Islam M, Ikram W, Naqvi SAA, Maqsood H, Saleem Y, Riaz A, Ravi P, Wang Z, Hussain SA, Warner JL, Odedina FT, Duma N, Singh P, Kehl KL, Kamran SC, Murad MH, Landman A, Van Allen E, Bryce AH. JAMA Oncol. 2023 Feb 1;9(2):180-187. doi: 10.1001/jamaoncol.2022.5511. PMID: 36416812
• Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer. Budhraja KK, McDonald BR, Stephens MD, Contente-Cuomo T, Markus H, Farooq M, Favaro PF, Connor S, Byron SA, Egan JB, Ernst B, McDaniel TK, Sekulic A, Tran NL, Prados MD, Borad MJ, Berens ME, Pockaj BA, LoRusso PM, Bryce A, Trent JM, Murtaza M. Sci Transl Med. 2023 Jan 11;15(678):eabm6863. doi: 10.1126/scitranslmed.abm6863. Epub 2023 Jan 11. PMID: 36630480 Free PMC article.
• Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Velez MG, Kosiorek HE, Egan JB, McNatty AL, Riaz IB, Hwang SR, Stewart GA, Ho TH, Moore CN, Singh P, Sharpsten RK, Costello BA, Bryce AH. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):479-483. doi: 10.1038/s41391-021-00430-4. Epub 2021 Jul 22. PMID: 34294873 Free PMC article.
• Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours. Karp DD, Camidge DR, Infante JR, Ames TD, Price MR, Jimeno J, Bryce AH. EClinicalMedicine. 2022 May 27;49:101430. doi: 10.1016/j.eclinm.2022.101430. eCollection 2022 Jul. PMID: 35747193 Free PMC article.
• Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. PLoS One. 2021 Apr 7;16(4):e0248097. doi: 10.1371/journal.pone.0248097. eCollection 2021. PMID: 33826614 Free PMC article. Clinical Trial.
• Clonal analyses of refractory testicular germ cell tumors. Barrett MT, Lenkiewicz E, Malasi S, Stanton M, Slack J, Andrews P, Pagliaro L, Bryce AH. PLoS One. 2019 Mar 14;14(3):e0213815. doi: 10.1371/journal.pone.0213815. eCollection 2019. PMID: 30870501 Free PMC article.
• Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencing. Bryce AH, Egan JB, Smadbeck JB, Johnson SH, Murphy SJ, Harris FR, Halling GC, Terra SBSP, Cheville J, Pagliaro L, Leibovich B, Costello BA, Vasmatzis G. Sci Rep. 2019 Mar 5;9(1):3586. doi: 10.1038/s41598-019-39956-y. PMID: 30837548 Free PMC article.
• Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227. doi: 10.1038/pcan.2016.71. Epub 2017 Jan 24. PMID: 28117385 Free PMC article. 

Read Dr. Bryce additional publications click here.